5-(4,5-dimethoxy-2-propyl-benzyl)-pyrimidine-2,4-diamine | 54236-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4,5-dimethoxy-2-propyl-benzyl)-pyrimidine-2,4-diamine
• 英文别名: 2,4-diamino-5-(2-n-propyl-4,5-dimethoxybenzyl)-pyrimidine；2,4-Diamino-5-(2-n-propyl-4,5-dimethoxybenzyl)-pyrimidin；5-[(4,5-Dimethoxy-2-propylphenyl)methyl]pyrimidine-2,4-diamine
• CAS: 54236-99-6
• 化学式: C₁₆H₂₂N₄O₂
• 分子量: 302.376
• InChiKey: RSAYXWLOHLCKLF-UHFFFAOYSA-N

物化性质

• 沸点：
  524.5±60.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  96.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 5-(4,5-dimethoxy-2-propyl-benzyl)-pyrimidine-2,4-diamine
  参考文献：
  名称：

  Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain

  摘要：

  P2X purinoceptors are ligand-gated ion channels whose endogenous ligand is ATP. Both the P2X(3) and P2X(2/3) receptor subtypes have been shown to play an important role in the regulation of sensory function and dual P2X(3)/P2X(2/3) antagonists offer significant potential for the treatment of pain. A high-throughput screen of the Roche compound collection resulted in the identification of a novel series of diaminopyrimidines; subsequent optimization resulted in the discovery of RO-4, a potent, selective and drug-like dual P2X(3)/P2X(2/3) antagonist. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.003

文献信息

• Process for substituted 5-benzyl-2,4-diamino-pyrimidines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04143227A1

  公开（公告）日：1979-03-06

  A process for preparing a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are lower alkoxy or taken together are METHYLENEDIOXY; R.sub.3 is lower alkyl or hydrogen, which comprises the step of reacting an aromatic compound of the formula ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are as previously described, with a diamino-pyrimidine of the formula ##STR3## wherein R.sub.4 is lower alkoxy, benzyloxy, hydroxy or halogen, in the presence of an inorganic or organic acid selected from the group consisting of ortho-phosphoric acid, poly-phosphoric acid, hydrohalic acids and tri-haloacetic acids, at a temperature in the range of from about 50.degree. C. to about 110.degree. C., is described.

  一种制备化合物的方法，该化合物的结构式为##STR1##其中R.sub.1和R.sub.2为较低的烷氧基或者结合在一起为亚甲二氧基；R.sub.3为较低的烷基或氢，包括以下步骤：将结构式为##STR2##其中R.sub.1、R.sub.2和R.sub.3如前所述，与结构式为##STR3##其中R.sub.4为较低的烷氧基、苄氧基、羟基或卤素，反应，在选择自正磷酸、聚磷酸、氢卤酸和三卤乙酸的无机或有机酸的情况下，在温度范围从约50摄氏度到约110摄氏度进行。
• Diaminopyrimidines as P2X3 and P2X2/3 antagonists
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2343282A1

  公开（公告）日：2011-07-13

  Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein,

  用于治疗由 P2X3 和/或 P2X2/3 受体拮抗剂介导的疾病的化合物和方法，这些方法包括向有需要的受试者施用有效量的式 (I) 化合物 或其药学上可接受的盐、溶液或原药，其中 D、X、Y、R1、R2、R3、R4、R5、R6、R7 和 R8 如本文所定义、
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP1725540B1

  公开（公告）日：2012-09-12
• US4143227A
  申请人：——

  公开号：US4143227A

  公开（公告）日：1979-03-06
• US4255574A
  申请人：——

  公开号：US4255574A

  公开（公告）日：1981-03-10